European Journal of Clinical Pharmacology

, Volume 25, Issue 1, pp 123–130 | Cite as

Formal theory of discrete drug dosing regimen adjustments

  • I. Janků
Originals

Summary

A formal theory of discrete drug dosing regimen adjustments has been developed, based on the recognition that in practical drug administration the possibilities for partition of a drug formulation are limited, and that only definite dosing intervals are acceptable in clinical practice. Normalization of the treatment regimen variables was used to reduce the innumerable cases of dosing regimens subject to adjustment to a limited number of categories. By replacing the dosing interval by the corresponding daily dosing frequency it was possible to associate with each treatment regimen a characteristic variable — the daily dose. The definition of the minimal normalized maintenance dose and the minimal normalized dosing frequency then permitted establishment for each case of a complete set of normalized dosing regimen adjustments, which consisted of all acceptable adjustments of both the variables of the regimen. This could be subdivided into several equivalency classes according to the value of the associated daily dose. The adjustment procedure of a dosing regimen can be regarded in general as a two stage process. In the first stage the normalized daily dose is selected according to the relative reduction in the total body clearance of the drug. This is followed, if necessary, by choice of which ever of the equivalent dosing regimens is more appropriate in the given situation. The theory also allows simultaneous change in both dosing regimen variables, thus enhancing the limited possibilities for adjustment. Its practical employment can be facilitated by use of a series of decision tables, although the formal character of the theory permits its implementation on mini- or desk-top computers.

Key words

pharmacokinetic theory dosing regimen adjustment drug dosage drug elimination impairment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krüger-Thiemer E (1960) Dosage schedule and pharmacokinetics in therapy. J Am Pharm Assoc (Sci Ed) 49: 311–313Google Scholar
  2. 2.
    Krüger-Thiemer E (1966) Formal theory of drug dosage regimens. I J Theor Biol 13: 212–235Google Scholar
  3. 3.
    Krüger-Thiemer E (1968) Pharmacokinetics and dose-concentration relationships. Proc Third International Pharmacology Meeting 1966, Pergamon Press, Oxford New York, Vol 7, pp 63–113Google Scholar
  4. 4.
    Krüger-Thiemer E, Bünger P (1965/1966) The role of therapeutic regimen in dosage design. Chemotherapie 10: 61–73, 129–144Google Scholar
  5. 5.
    Wagner JG, Northam JI, Alway CD, Carpenter DS (1965) Blood levels of drug at the equilibrium state of after multiple dosing. Nature 207: 1301–1302Google Scholar
  6. 6.
    Wagner JG (1967) Drug accumulation. J Clin Pharmacol 7: 84–88Google Scholar
  7. 7.
    Di Santo A, Chodos D, Halberg F (1975) Chronoavailability of the three erythromycin test preparations assessed by each of 4 indices: Time to peak, peak, nadir and area. Chronobiologia 2 [Suppl 1]: 17Google Scholar
  8. 8.
    Clench J, Reinberg A, Dziewanowska Z, Ghata J, Smolensky M (1981) Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol 20: 359–369Google Scholar
  9. 9.
    Theeuwes F (1981) Drug delivery systems. Pharmacol Ther 13: 149–191Google Scholar
  10. 10.
    Gatley MS (1968) To be taken as directed. J R Coll Gen Pract 16: 39–44Google Scholar
  11. 11.
    Haynes RB, Sackett DL, Taylor DW, Roberts RS, Johnson AL (1977) Manipulation of the therapeutic regimen to improve compliance: Conceptions and misconceptions. Clin Pharmacol Ther 22: 125–130Google Scholar
  12. 12.
    Tozer TN (1974) Nomogram for modification of dosage regimens in patients with chronic renal function impairment. J Pharmacokinet Biopharm 2: 13–28Google Scholar
  13. 13.
    Dettli L, Spring P, Habersang R (1970) Drug dosage in patients with kidney disease. Postgrad Med 46 [Suppl]: 32–35Google Scholar
  14. 14.
    Dettli L, Spring P, Ryter S (1971) Multiple dose kinetics and drug dosage in patients with kidney disease. Acta Pharmacol (KbH) 29 [Suppl]: 211–224Google Scholar
  15. 15.
    Giusti DL, Hayton WL (1973) Dosage regimen adjustments in renal impairment. Drug Intell Clin Pharm 7: 382–387Google Scholar
  16. 16.
    Welling PG, Craig WA, Kunin CM (1975) Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther 18: 45–52Google Scholar
  17. 17.
    Chennavasin P, Brater DC (1981) Nomograms for drug use in renal disease. Clin Pharmacokinet 6: 193–214Google Scholar
  18. 18.
    Williams RL, Benet LZ (1980) Drug pharmacokinetics in cardiac and hepatic disease. Ann Rev Pharmacol Toxicol 20: 389–413Google Scholar
  19. 19.
    Williams RL, Mamelok RD (1980) Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 5: 528–547Google Scholar
  20. 20.
    Dettli L (1974) Individualization of drug dosage in patients with renal disease. Med Clin North Am 58: 977–985Google Scholar
  21. 21.
    Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1: 126–134Google Scholar
  22. 22.
    Dettli L (1977) Elimination kinetics and dosage adjustments in patients with kidney disease. Progr Pharmacol 1: 1–34Google Scholar
  23. 23.
    Bjornsson TD (1979) Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 4: 200–222Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • I. Janků
    • 1
  1. 1.Institute of PharmacologyCzechoslovak Academy of SciencesPragueCzechoslovakia

Personalised recommendations